Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Merck partners with Agenus for cancer immunotherapies

Executive Summary

Agenus Inc. (developing checkpoint modulators, heat-shock protein vaccines, and adjuvants for cancer and infectious diseases) agreed to use its 4-Antibody Retrocyte Display platform to discover fully human antibodies against two of Merck & Co. Inc.’s immune checkpoint targets for cancer. Merck gets rights to develop and sell the resulting compounds.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register